CN101797337B - Medicine containing Guadisu - Google Patents
Medicine containing Guadisu Download PDFInfo
- Publication number
- CN101797337B CN101797337B CN2010101487454A CN201010148745A CN101797337B CN 101797337 B CN101797337 B CN 101797337B CN 2010101487454 A CN2010101487454 A CN 2010101487454A CN 201010148745 A CN201010148745 A CN 201010148745A CN 101797337 B CN101797337 B CN 101797337B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- hepatitis
- elaterin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 229940079593 drug Drugs 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- NDYMQXYDSVBNLL-UHFFFAOYSA-N (9beta,10alpha,16alpha,23E)-25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-1,5,23-triene-3,11,22-trione Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)C=CC(C)(C)OC(=O)C)C(O)CC3(C)C1CC=C1C2C=C(O)C(=O)C1(C)C NDYMQXYDSVBNLL-UHFFFAOYSA-N 0.000 claims description 13
- VVBWBGOEAVGFTN-SYJGCRHZSA-N Cucurbitacin P Chemical compound C([C@H]1[C@]2(C)C[C@@H](O)[C@@H]([C@]2(CC(=O)[C@]11C)C)[C@@](C)(O)C(=O)CCC(C)(O)C)C=C2[C@H]1C[C@@H](O)[C@@H](O)C2(C)C VVBWBGOEAVGFTN-SYJGCRHZSA-N 0.000 claims description 13
- VVBWBGOEAVGFTN-UHFFFAOYSA-N dihydrocucurbitacin F Natural products CC12C(=O)CC3(C)C(C(C)(O)C(=O)CCC(C)(O)C)C(O)CC3(C)C1CC=C1C2CC(O)C(O)C1(C)C VVBWBGOEAVGFTN-UHFFFAOYSA-N 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 102000003929 Transaminases Human genes 0.000 claims description 4
- 108090000340 Transaminases Proteins 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 2
- 241000555682 Forsythia x intermedia Species 0.000 claims description 2
- 241000245240 Lonicera Species 0.000 claims description 2
- 241000283956 Manis Species 0.000 claims description 2
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 2
- 241000180649 Panax notoginseng Species 0.000 claims description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 2
- 241001038563 Pseudostellaria Species 0.000 claims description 2
- 241001529553 Scoparia <angiosperm> Species 0.000 claims description 2
- 239000010231 banlangen Substances 0.000 claims description 2
- 230000006837 decompression Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 abstract description 16
- 231100000283 hepatitis Toxicity 0.000 abstract description 12
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 230000001154 acute effect Effects 0.000 description 7
- 206010067125 Liver injury Diseases 0.000 description 6
- 208000002672 hepatitis B Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 239000003390 Chinese drug Substances 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 206010019668 Hepatic fibrosis Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 231100000012 chronic liver injury Toxicity 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005331 Hepatitis D Diseases 0.000 description 1
- 206010019754 Hepatitis cholestatic Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 231100000838 cholestatic hepatitis Toxicity 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- SPPIIOPGDLITJE-VLQRKCJKSA-N diazanium;(2s,3s,4s,5r,6s)-6-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-5-[(2r,3r,4s,5s,6s)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy-3,4-dihy Chemical compound N.N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O SPPIIOPGDLITJE-VLQRKCJKSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000037890 multiple organ injury Diseases 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Group | Number of animals | GOT (active unit) | GPT (active unit) |
The normal control group | 10 | 21.68±16.95 | 48.91±17.85 |
Model control group | 10 | 252.86±73.58 | 306.45±58.47 |
Pure Chinese drug-treated group | 10 | 177.86±54.37 | 229.52±50.39 |
The Cucurbitacin P.E Elaterin group | 10 | 96.91±33.71 | 190.52±22.71 |
The compositions group | 10 | 75.74±20.03 | 98.89±37.73 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101487454A CN101797337B (en) | 2010-04-15 | 2010-04-15 | Medicine containing Guadisu |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101487454A CN101797337B (en) | 2010-04-15 | 2010-04-15 | Medicine containing Guadisu |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101797337A CN101797337A (en) | 2010-08-11 |
CN101797337B true CN101797337B (en) | 2011-12-21 |
Family
ID=42593278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101487454A Expired - Fee Related CN101797337B (en) | 2010-04-15 | 2010-04-15 | Medicine containing Guadisu |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101797337B (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1058163C (en) * | 1995-06-02 | 2000-11-08 | 丁殿利 | Yigan Kangyangsan powder for curing hepatitis B |
CN1318377A (en) * | 2000-04-20 | 2001-10-24 | 卢忠 | Hepatosis treating Chinese medicine |
CN100356960C (en) * | 2006-07-06 | 2007-12-26 | 张砚 | Synergistic medicinal composition for treating hepatitis |
-
2010
- 2010-04-15 CN CN2010101487454A patent/CN101797337B/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN101797337A (en) | 2010-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101810694B (en) | Traditional Chinese medicine and western medicine composition for adjunctive therapy of hepatitis | |
CN100356960C (en) | Synergistic medicinal composition for treating hepatitis | |
CN100353992C (en) | Medicine for auxiliary treating hepatitis | |
CN100444865C (en) | Synergistic medicinal composition containing dicyclic alcohol | |
CN101843822B (en) | Medicinal composition containing traditional Chinese medicine extract | |
CN100421704C (en) | Drug comprising biphenyldicarboxylate | |
CN100366283C (en) | Compositions comprising biphenyldicarboxylate | |
CN100363040C (en) | Medicinal compositions comprising biphenyldicarboxylate | |
CN100363035C (en) | Cooperative medicinal composition comprising biphenyldicarboxylate and traditional Chinese medicine extract | |
CN100421697C (en) | Synergistic medicinal composition containing diammonium glycyrrhizinate and Chinese medicine | |
CN100421690C (en) | Chinese-western medicine composition for treating hepatitis | |
CN101502631B (en) | Synergistic medicament composition containing Aolamite and Chinese medicine extract | |
CN100356958C (en) | Synergistic medicinal composition for treating hepatitis | |
CN101797337B (en) | Medicine containing Guadisu | |
CN101810776B (en) | Curbitacin-containing medicine | |
CN101708282B (en) | Medicine containing glucurolactone | |
CN100569279C (en) | The medicine that contains glucurolactone | |
CN101850003B (en) | Traditional Chinese medicine and western medicine compound for protecting liver and decreasing enzyme | |
CN101810759B (en) | Curbitacin-containing medicine | |
CN100434096C (en) | Drug for treating hepatitis comprising biphenyldicarboxylate | |
CN101837064B (en) | Epomediol-containing medicament composition for protecting liver and decreasing enzyme | |
CN100353993C (en) | Medicine for auxiliary treating hepatitis | |
CN100450507C (en) | Chinese traditional medicine and western medicine composition for treating hepatitis | |
CN100444866C (en) | Synergistic medicinal composition | |
CN100353994C (en) | Synergistic medicinal composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: NINGBO JIANGBEI WEIMAN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHANG DAYU Effective date: 20111018 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Chunjie Inventor after: Zhang Dayu Inventor before: Zhang Dayu |
|
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100070 FENGTAI, BEIJING TO: 315021 NINGBO, ZHEJIANG PROVINCE Free format text: CORRECT: INVENTOR; FROM: ZHANG DAYU TO: ZHANG CHUNJIE ZHANG DAYU |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20111018 Address after: Jiangbei District Yongjiang street 315021 Ring Road East of Zhejiang city of Ningbo province No. 134 room C-220 Applicant after: NINGBO JIANGBEI WEIMAN BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: 100070, No. 18, building eight, 188, base station, South Fourth Ring Road West, Beijing, Fengtai District Applicant before: Zhang Dayu |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WANG FENGYU Free format text: FORMER OWNER: NINGBO JIANGBEI WEIMAN BIOTECHNOLOGY CO., LTD. Effective date: 20130218 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 315021 NINGBO, ZHEJIANG PROVINCE TO: 300000 HEXI, TIANJIN |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130218 Address after: 300000 Tianjin city Hexi District Zhujiang Road No. 14 Building 7 City Park Gate No. 502 Patentee after: Wang Fengyu Address before: Jiangbei District Yongjiang street 315021 Ring Road East of Zhejiang city of Ningbo province No. 134 room C-220 Patentee before: NINGBO JIANGBEI WEIMAN BIOLOGICAL TECHNOLOGY Co.,Ltd. |
|
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300000 Tianjin city Hexi District Zhujiang Road No. 14 Building 7 City Park Gate No. 502 Patentee after: Wang Fengyu Address before: 300000 Tianjin city Hexi District Zhujiang Road No. 14 Building 7 City Park Gate No. 502 Patentee before: Wang Fengyu |
|
ASS | Succession or assignment of patent right |
Owner name: HAIAN CHANGDA TECHNOLOGY TRANSFER CENTER CO., LTD. Free format text: FORMER OWNER: WANG FENGYU Effective date: 20131218 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 300000 HEXI, TIANJIN TO: 226601 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131218 Address after: 226601 No. 8 Yingbin Road, Haian County, Nantong, Jiangsu Patentee after: HAIAN CHANGZHOU UNIVERSITY TECHNOLOGY TRANSFER CENTER Co.,Ltd. Address before: 300000 Tianjin city Hexi District Zhujiang Road No. 14 Building 7 City Park Gate No. 502 Patentee before: Wang Fengyu |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221226 Address after: Room 610, Building 3, Science and Technology Mansion, Linyi Hi tech Industrial Development Zone, Shandong Province, 276000 Patentee after: Linyi Enke Development and Construction Co.,Ltd. Address before: No.8 Yingbin Road, Hai'an County, Nantong City, Jiangsu Province Patentee before: HAIAN CHANGZHOU UNIVERSITY TECHNOLOGY TRANSFER CENTER Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111221 |
|
CF01 | Termination of patent right due to non-payment of annual fee |